ABSTRACT
Mutations in the TUBB4A gene have been identified so far in two neurodegenerative disorders with extremely different clinical features and course: whispering dysphonia, also known as dystonia type 4 (DYT4), and hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). We describe a patient with slowly progressive spastic paraparesis, segmental dystonia, intellectual disability, behavioral problems, and evidence of permanent, incomplete myelination associated with progressive cerebellar atrophy. Whole exome sequencing revealed a novel E410K de novo heterozygous mutation in the TUBB4A gene. The clinical and radiological picture of our patient is different from the classic phenotype; thus, it expands the phenotypic variation of TUBB4A-gene-related disorders.
Subject(s)
Leukoencephalopathies/genetics , Mutation , Neurodegenerative Diseases/genetics , Phenotype , Tubulin/genetics , Child , Heterozygote , Humans , Leukoencephalopathies/complications , Male , Neurodegenerative Diseases/complicationsSubject(s)
Leukoencephalopathies/genetics , Mutation , Neurodegenerative Diseases/genetics , Phenotype , Tubulin/genetics , Humans , MaleABSTRACT
PURPOSE: Inter-subject variability in oral drug absorption is usually reported using bioavailability, which has the components: fraction absorbed (fa), fraction passing the gut wall (fg) and fraction escaping hepatic metabolism (fh). In this study, we sought to separate the absorption (fa∗fg) and elimination (fh) components of bioavailability to study variability of absorption and to investigate the effect of formulations, gastric pH and food on absorption variability. METHODS: Four compounds from the AstraZeneca database with a range of reported bioavailabilities (high, intermediate 1&2 and low) were selected. First, a disposition model using intravenous data was developed; Second, intrinsic clearance and hence hepatic extraction ratio was estimated based on the "well stirred" model; lastly, the oral data were included to enable estimation of fa∗fg as a separate component to hepatic extraction. Population pharmacokinetic model fitting was undertaken with NONMEM v.7.2. RESULTS: The limiting step in absorption for intermediate 1 was dissolution rate and fa∗fg variability increased under elevated gastric pH (15% vs. 38%, respectively). Absorption of solution formulation intermediate 2 increased by 17% in the presence of food but the prolonged release formulation's absorption didn't differ under fasted or fed state. Variability wasn't affected by food for both formulations (~30%). For the low bioavailable compound, variability decreased when formulated as a prolonged-release formulation (39% vs. 15%). CONCLUSIONS: The method described here enables an exploration of drug absorption inter-subject variability using population pharmacokinetics. Implementation of such an approach may aid the formulation design process through a better understanding of the factors affecting oral drug absorption variability.
Subject(s)
Chemistry, Pharmaceutical/methods , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Drug Discovery/methods , Intestinal Absorption/physiology , Administration, Oral , Adult , Biological Availability , Delayed-Action Preparations/administration & dosage , Gastric Acid , Humans , Hydrogen-Ion Concentration , Liver/metabolism , Middle Aged , Models, Biological , Young AdultABSTRACT
Variability in oral drug absorption is a well-known phenomenon, but it is often overlooked for its potential effects in oral drug delivery. Understanding the mechanisms behind absorption variability is crucial to understanding and predicting drug pharmacokinetics. In this study, the solubility of furosemide and dipyridamole - drugs known to have highly variable oral bioavailabilities - was investigated in individual ileostomy fluids from 10 subjects with ulcerative colitis. For comparison, drug solubility was also determined in pooled upper gastrointestinal fluids from healthy human subjects and simulated intestinal fluids. Ileostomy fluid characterization revealed high variability in buffer capacity and to a lesser degree for pH. Drug solubility in ileostomy fluids showed high variability. Correlation analysis revealed that dipyridamole solubility in these fluids is pH-dependent, whereas furosemide solubility was highly correlated to buffer capacity and pH. The implications of these results might partly explain the high variability in bioavailability in vivo, assuming that most of the observed variability is due to the absorption, and not the elimination, process.
Subject(s)
Dipyridamole/chemistry , Furosemide/chemistry , Intestinal Secretions/chemistry , Administration, Oral , Biological Availability , Buffers , Colitis, Ulcerative/metabolism , Colitis, Ulcerative/surgery , Dipyridamole/administration & dosage , Dipyridamole/pharmacokinetics , Furosemide/administration & dosage , Furosemide/pharmacokinetics , Humans , Hydrogen-Ion Concentration , Ileostomy , Intestinal Absorption , Models, Biological , SolubilityABSTRACT
To repair a recurrent strangulated umbilical hernia in a cirrhotic patient with refractory ascites, we used a minimally invasive procedure. The laparoscopic repair included a release of the incarcerated small bowel loop and secure of a dual Gortex mesh onto the fascial rim. Our satisfactory long-term results should encourage surgeons to adapt this surgical approach.